The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients

Bremholm, Lasse; Hornum, Mads; Andersen, Ulrik B.; Hartmann, Bolette; Holst, Jens J.; Jeppesen, Palle Bekker

doi:10.1016/j.regpep.2011.03.003

Cited by 85 publications

(62 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GLP-2 has several beneficial actions in the gut, including increased mucosal growth, blood flow and digestive and absorptive function [12,13,22,23]. Although recent reports have shown that GLP-2 exerts an anti-inflammatory action [14, , 10…”

Section: Glp-2 Is An Intestinotrophic Peptide That Is Secreted By Entmentioning

confidence: 99%

GLP-2 Suppresses LPS-Induced Inflammation in Macrophages by Inhibiting ERK Phosphorylation and NF-κB Activation

Xie

Liu

et al. 2014

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

Section: Glp-2 Is An Intestinotrophic Peptide That Is Secreted By Entmentioning

confidence: 99%

GLP-2 Suppresses LPS-Induced Inflammation in Macrophages by Inhibiting ERK Phosphorylation and NF-κB Activation

Xie

Liu

et al. 2014

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Repeated administration of GLP-2 promotes the expansion of the intestinal mucosa, via the stimulation of crypt cell growth and the reduction of enterocyte apoptosis [Drucker et al 1996]. Exogenous GLP-2 administration inhibits gastric acid secretion and gastric emptying [Wojdemann et al 1998[Wojdemann et al , 1999, stimulates intestinal blood flow [Guan et al 2006;Bremholm et al 2009Bremholm et al , 2011, increases intestinal barrier function [Benjamin et al 2000;Cani et al 2009] and enhances nutrient and fluid absorption in both preclinical and clinical models [Brubaker et al 1997;Jeppesen et al 2001Jeppesen et al , 2009. However, a paradoxical resistance to exogenous GLP-2-induced adaptation was reported in piglets [Pereira-Fantini et al 2008].…”

Section: Glucagon-like Peptide 2 and Teduglutidementioning

confidence: 99%

Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome

Jeppesen

2012

Therap Adv Gastroenterol

Self Cite

View full text Add to dashboard Cite

Short bowel syndrome results from surgical resection, congenital defect or diseaseassociated loss of absorption. Parenteral support (PS) is lifesaving in patients with short bowel syndrome and intestinal failure who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Together, the symptoms of short bowel syndrome and the inconvenience and complications in relation to PS (e.g. catheter-related blood steam infections, central thrombosis and intestinal failure associated liver disease) may impair the quality of life of patients. The aim of treatment is to maximize intestinal absorption, minimize the inconvenience of diarrhea, and avoid, reduce or eliminate the need for PS to achieve the best possible quality of life for the patient. Conventional treatments include dietary manipulations, oral rehydration solutions, and antidiarrheal and antisecretory treatments. However, the evidence base for these interventions is limited and treatments that improve the structural and functional integrity of the remaining intestine are needed. Teduglutide, an analog of glucagon-like peptide 2, improves intestinal rehabilitation by promoting mucosal growth and possibly by restoring gastric emptying and secretion, thereby reducing intestinal losses and promoting intestinal absorption. In a 3-week, phase II balance study, teduglutide reduced diarrhea by around 700 g/day and fecal energy losses by around 0.8 MJ/day. In two randomized, placebo-controlled, 24-week, phase III studies, similar findings were obtained when evaluating the fluid composite effect, which is the sum of the beneficial effects of teduglutide -reduction in the need for PS, increase in urine production and reduction in oral fluid intake. The fluid composite effect reflects the increase in intestinal fluid absorption (and the concomitant reduction in diarrhea) and may be used in studies in which metabolic balance assessments are not performed. In studies of up to 24 weeks' duration, teduglutide appears to be safe and well tolerated. Treatment with teduglutide was associated with enhancement or restoration of the structural and functional integrity of the remaining intestine with significant intestinotrophic and proabsorptive effects, facilitating a reduction in diarrhea and an equivalent reduction in the need for PS in patients with short bowel syndrome and intestinal failure.

show abstract

“…Finally, Glp-2 increases hexose transportation and inhibits apoptosis by decreasing intestinal motility and permeability. Externally administered Glp-2 has many effects on the intestinal system, such as increasing intestinal blood flow (6)(7)(8)(9) and intestinal barrier function (10,11). In other studies, Glp-2 has also been found to have an antiinflammatory effect (12,13).…”

Section: Introductionmentioning

confidence: 95%

Does Glp-2 have a protective effect on cerebral ischemia/reperfusion model?

Topaloğlu¹,

Memi²,

Kaner³

et al. 2015

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: To investigate the neuroprotective effects of glucagon-like peptide 2 (Glp-2), which increases cerebral blood flow, on the hippocampal complex after cerebral ischemia/reperfusion (I/R) injury in rats.Materials and methods: Animals were randomized into 4 groups: sham, I/R + 0.9% NaCl, I/R + pre-Glp-2, and I/R + post-Glp-2. Cerebral ischemia was performed via the occlusion of the bilateral internal carotid artery for 40 min and continued with a reperfusion process. At the end of 6 h of reperfusion, animals were decapitated in all groups and brain tissues were removed. Malondialdehyde (MDA) and natural intracellular antioxidant glutathione (GSH) levels and myeloperoxidase (MPO) activities were measured in the left hippocampal tissue. The right hippocampal tissues of all group members were taken for histopathologic study.Results: MDA levels and MPO activities increased from Group I to Group II and decreased from Group II to Groups III and IV. On the other hand, GSH levels were not significantly different among the groups. The number of apoptotic hippocampal tissue cells increased from Group I to Group II and decreased from Group II to Groups III and IV. Conclusion:Our preliminary study revealed that Glp-2 treatment may decrease oxidative damage from I/R in cerebral tissue.

show abstract

The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients

Cited by 85 publications

References 18 publications

GLP-2 Suppresses LPS-Induced Inflammation in Macrophages by Inhibiting ERK Phosphorylation and NF-κB Activation

GLP-2 Suppresses LPS-Induced Inflammation in Macrophages by Inhibiting ERK Phosphorylation and NF-κB Activation

Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome

Does Glp-2 have a protective effect on cerebral ischemia/reperfusion model?

Contact Info

Product

Resources

About